09:49 AM EST - ProMetic Life Sciences Inc. : Has amended its licensing agreement originally entered into with Hematech BioTherapeutics Inc., in May 2012. ProMetic has reacquired the rights initially granted to Hematech in the License Agreement, to a 50% share of the worldwide profits related to plasminogen congenital deficiency sales. ProMetic Life Sciences Inc.
shares T.PLI are trading down $0.02 at $2.17.
